ArticleJournal of ophthalmic inflammation and infection2025
Long-term management of recurrent uveitis associated with autoimmune lymphoproliferative syndrome.
Article in Journal of ophthalmic inflammation and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe purpose of this case report is to describe the long-term findings and management of recurrent uveitis in a patient with autoimmune lymphoproliferative syndrome (ALPS). CASE OBSERVATION: A 25-year-old female with a history of ALPS and previous uveitis flares presented with reduced vision and pain in the left eye. Uveitis flares began at age 4 and continued into adulthood prompting multiple medical regimen changes. Ocular involvement included anterior uveitis, posterior uveitis, and panuveitis. The laterality of uveitis flares favored the left eye, however bilateral episodes were documented. The patient was diagnosed with recurrent anterior uveitis and treated with topical corticosteroids with subsequent resolution of her symptoms. However, the patient continued to develop recurrent uveitis prompting low-dose long-term maintenance treatment with topical corticosteroids. Additionally, methotrexate was added which led to uveitis resolution and inactive disease for over a year on this treatment regimen.
conclusionsUveitis secondary to chronic autoimmune disease, such as ALPS, offer long-term challenges for ocular health management. Due to the recurrent nature of uveitis flares in patients with ALPS, long-term ophthalmic and systemic management may be warranted with low-dose maintenance topical corticosteroid or systemic immunomodulation. Response to topical and systemic therapy can be highly patient specific. Complex side effect profiles of many systemic immunotherapies make drug tolerability an important treatment consideration. Multidisciplinary coordination of systemic immunosuppression should be tailored to the patient's anti-inflammatory needs, as well as careful monitoring of adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.